Article: “Abundant albumin offers opportunities for CDMOs”
Limited access to recombinant albumin holds back the work of Contract Development and Manufacturing Organisations (CDMOs). The market’s preference for chemically defined media has increased demand for recombinant albumin as a replacement for animal-derived proteins. Alternative sources have limitations, but new technology allows CDMOs to reduce costs and produce consistent, high-quality recombinant albumin using baker’s yeast. This benefits CDMOs by offering more competitively priced cell line development programs and increasing the likelihood of products reaching the market. Disrupting the monopoly of albumin supply brings benefits to cell and gene therapy and monoclonal antibody projects.
Introduction:
The article discusses the challenges faced by Contract Development and Manufacturing Organisations (CDMOs) in accessing recombinant albumin, a critical ingredient in cell culture media for the manufacturing of biological therapeutics. The market’s preference for chemically defined media has increased the demand for recombinant albumin, leading to high prices and limited supply. Alternative sources of recombinant albumin have fallen short due to various drawbacks. However, new technology using Quantitative Trait Loci (QTL) allows CDMOs to produce consistent, high-quality, and affordable recombinant albumin using baker’s yeast. This development offers opportunities for CDMOs to reduce costs, increase competitiveness, and gain more value from their manufacturing processes.
- The growing preference for chemically defined media has increased the demand for recombinant albumin in cell culture media.
- High prices and limited supply of recombinant albumin have been a challenge for CDMOs.
- Alternative sources of recombinant albumin have drawbacks such as impurities, high processing costs, and batch-to-batch inconsistencies.
- New technology using Quantitative Trait Loci (QTL) allows CDMOs to produce consistent, high-quality, and affordable recombinant albumin using baker’s yeast.
- Reducing the cost of cell culture media helps CDMOs offer competitively priced services, improve profit margins, and gain market share.
Conclusion:
The development of new technology that enables the production of abundant and high-quality recombinant albumin using baker’s yeast offers opportunities for CDMOs. By reducing costs and improving manufacturing processes, CDMOs can offer more competitively priced services, increase their market share, and encourage more products to reach the market. This technology also mitigates the risks of relying on a few suppliers and opens up opportunities for innovation in cell and gene therapy. Overall, the availability of abundant albumin has the potential to drive growth and success for CDMOs in the biomanufacturing industry.
